Latest papers

The human trypanolytic factor: a drug shaped naturally.

Antihyperglycaemic and antihyperlipidaemic effect of poly-constituents, in aqueous and chloroform extracts, of Withania coagulans Dunal in experimental type 2 diabetes mellitus in rats.

Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles.

The Scl1 of M41-type group A Streptococcus binds the high-density lipoprotein.

Genetics. Kidney disease is parasite-slaying protein's downside.

Calmodulin interacts with ATP binding cassette transporter A1 to protect from calpain-mediated degradation and upregulates high-density lipoprotein generation.

Protective effect of high-density lipoprotein-based therapy in a model of embolic stroke.

ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation.

Medicine. Tackling two diseases with HDL.

Diabetes in relation to biliary tract cancer and stones: a population-based study in Shanghai, China.

A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome.

The carboxyl-terminal segment of apolipoprotein A-V undergoes a lipid-induced conformational change.

A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice.

Effects of human follicular fluid and high-density lipoproteins on early spermatozoa hyperactivation and cholesterol efflux.

Targeted PPAR{gamma} deficiency in alveolar macrophages disrupts surfactant catabolism.

Application of gel permeation HPLC for lipoprotein profiling in dogs.

Selenium supplementation and the incidence of preeclampsia in pregnant Iranian women: a randomized, double-blind, placebo-controlled pilot trial.

Effects of high-density lipoprotein on endothelium-dependent vasorelaxation.

Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug.

VLDL lipolysis products increase VLDL fluidity and convert apolipoprotein E4 into a more expanded conformation.